Trials / Completed
CompletedNCT06555783
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 93 (actual)
- Sponsor
- Alkermes, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to measure the safety and decrease in sleepiness in subjects with narcolepsy type 2 (NT2) when taking ALKS 2680 tablets compared to placebo tablets.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALKS 2680 | Oral tablet containing ALKS 2680 |
| DRUG | Placebo | Oral tablet containing placebo for once daily administration |
Timeline
- Start date
- 2024-07-26
- Primary completion
- 2025-11-11
- Completion
- 2025-11-21
- First posted
- 2024-08-15
- Last updated
- 2026-02-27
Locations
47 sites across 8 countries: United States, Australia, Belgium, Czechia, France, Italy, Netherlands, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06555783. Inclusion in this directory is not an endorsement.